{"schema_version":"secwatch.filing_event.v1","accession":"0001609550-23-000061","form_type":"8-K","ticker":"INSP","cik":"0001609550","company_name":"Inspire Medical Systems, Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.766608+00:00","generated_at":"2026-06-08T15:30:28.057753+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Inspire Medical Q3 revenue $153.3M (+40% YoY); raises FY2023 guidance to $608-612M","bullets":["Net loss narrowed to $8.5M ($0.29 per share) from $16.8M ($0.60) YoY.","U.S. revenue $147.5M (+39%); OUS revenue $5.8M (+99%). Gross margin improved to 84.1%.","Added 62 new U.S. implant centers (total 1,107) and 13 new sales territories (total 274).","Surpassed 50,000 patients treated with Inspire therapy globally.","FY2023 revenue guidance raised to $608-612M (49-50% growth); gross margin guidance maintained at 83-85%."],"urls":{"canonical":"https://secwatch.observer/filing/0001609550-23-000061","json":"https://secwatch.observer/filing/0001609550-23-000061.json","markdown":"https://secwatch.observer/filing/0001609550-23-000061.md","text":"https://secwatch.observer/filing/0001609550-23-000061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1609550/000160955023000061/0001609550-23-000061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1609550/000160955023000061/insp-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T15:30:28.057753+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"43ae3ced960d704a9e8d057348e186af506f6415","claim":"Inspire Medical Systems, Inc. reported full year 2023 results: revenue $608 million to $612 million. Guidance raised.","evidence_excerpt":"Inspire is increasing and narrowing its full year 2023 revenue guidance to between $608 million to $612 million, which represents growth of 49% to 50% over full year 2022 revenue of $407.9 million. This compares to the prior revenue guidance of $600 million to $610 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1609550/000160955023000061/0001609550-23-000061-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"$608 million to $612 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}